BVF PARTNERS L P/IL - 11 Jul 2022 Form 3 Insider Report for ESSA Pharma Inc. (EPIX)

Role: 10%+ Owner
Signature: BVF Partners L.P., By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President
Issuer symbol: EPIX
Transactions as of: 11 Jul 2022
Net transactions value: $0
Form type: 3
Filing time: 21 Jul 2022, 19:26:56 UTC
Previous filing: 27 Jun 2022
Next filing: 11 Aug 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	EPIX	Common Stock						4,712,590	11 Jul 2022	Direct	F1, F2
holding	EPIX	Common Stock						3,491,779	11 Jul 2022	Direct	F1, F3
holding	EPIX	Common Stock						357,472	11 Jul 2022	Direct	F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	EPIX	Pre-funded Warrants							11 Jul 2022	Common Stock	1,481,634	$0.000100	Direct	F1, F2, F5
holding	EPIX	Pre-funded Warrants							11 Jul 2022	Common Stock	1,235,030	$0.000100	Direct	F1, F3, F5
holding	EPIX	Pre-funded Warrants							11 Jul 2022	Common Stock	203,336	$0.000100	Direct	F1, F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This Form 3 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
F2	Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
F3	Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
F4	Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
F5	The Issuer previously issued pre-funded warrants to the Reporting Persons which are exercisable into shares of common stock at an exercise price equal to $0.0001 per share, which have an exercise period of 60 months (August 27, 2024) from the date of issuance. Each pre-funded warrant is exercisable into 1 share of common stock. The pre-funded warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own more than 9.99% of the Issuer's outstanding shares of common stock.